ReShape Lifesciences Inc

ReShape Lifesciences — EnteroMedics — Technical Presentation (February 2013)

13 slides from ReShape Lifesciences's technical presentation, Feb 8, 2013

  1. Slide 1: ReCharge Pivotal Trial Results

    Exhibit 99.1 ReCharge Pivotal Trial Results February 7, 2013 Copyright © 2013

  2. Slide 2: Study Design

    Study Design 2 Prospective, double-blind, sham controlled randomized trial in 239 subjects (233 implanted) Co-Primary Efficacy Endpoint: At least 10% difference in %EWL by super-superiority of treatment over sham control (BMI method at 12 months, post randomization) Co-Primary Efficacy endpoint: 55%

  3. Slide 3: Results Overview - ITT Population

    Results Overview - ITT Population 3 Overall outcome: Excellent benefit/risk ratio at 12 months Efficacy – Percent EWL: Clinically meaningful, statistically significant superiority over Sham Control Efficacy – Responder analysis: Strongly in favor of VBLOC Safety: Primary endpoint met

  4. Slide 4: Efficacy Results: Mean %EWL in ITT Population

    Efficacy Results: Mean %EWL in ITT Population 4 Excess Weight Loss (%) at 12 months (BMI) Treated Control Difference N Mean ± SD 24.4 ± 23.6 15.9 ± 17.7 8.5 ± 21.9 [95% CI] [20.8, 28.1] [11.9, 19.9] [3.1, 13.9] Super-superiority P-value 0.705 Superiority P-value 0.002

  5. Slide 5: Mean %EWL (BMI Method) by Visit

    Mean %EWL (BMI Method) by Visit 30 Ll Active Mean %sEWL (BMI Method) 15 20 Pd 10 ° 3 6 9 12 Visit Month EnteroMedics

  6. Slide 6: Efficacy Results: Responder Analysis in ITT Population

    Efficacy Results: Responder Analysis in ITT Population 6 Percent EWL achieved (BMI) Treated N=162 Control N=77 Odds Ratio p-Value 20% 52.5% (85) 32.5% (25) 2.3 (1.3, 4.1) .004 25% 38.3% (62) 23.4% (18) 2.1 (1.1, 3.8) .02 30% 30.2% (49) 18.2% (14) 2.0 (1.0, 3.9) .047 35% 25.9% (42) 9.1% (7) 3.5 (1.5,

  7. Slide 7: Odds Ratio for Various Response Rates Treated vs. Sham Control

    Odds Ratio for Various Response Rates Treated vs. Sham Control 7

  8. Slide 8: Per Protocol Population Efficacy Results

    Per Protocol Population Efficacy Results 8 Excess Weight Loss (%) at 12 months (BMI ) Treated Control Difference N Mean ± SD 26.3 ± 23.8 17.3 ± 18.1 8.9 ± 22.2 [95% CI] [22.4, 30.2] [12.9, 21.8] [3.0, 14.8] P-value (Delta = 10%) 0.640 P-value (Delta = 0%) 0.003 Percent EWL achieved (BMI) Treated N=1

  9. Slide 9: Safety Results

    Safety Results 9 • No deaths, no unanticipated adverse device effects • Implant/revision procedure, device, therapy-related SAEs in treated subjects (primary safety endpoint): 3.1% vs. 15% pre- specified limit, CI (1.0, 7.1%); p<0.0001 • 93% of subjects were active in the blinded trial at 12 months

  10. Slide 10: Cardiovascular Safety

    Cardiovascular Safety 10 Measure Visit Type Treated N Mean SD Systolic Blood Pressure (mmHg) 6 months -6.6 12.7 12 months -5.5 14.2 Diastolic Blood Pressure (mmHg) 6 months -3.4 8.9 12 months -2.8 9.6 Heart Rate (bpm) 6 months -4.4 11.9 12 months -3.6 10.3

  11. Slide 11: Overview of Results: ReCharge Pivotal Trial

    11 Overview of Results ReCharge Pivotal Trial By: Robert D. Gibbons, Ph.D.

  12. Slide 12: Conclusions

    Conclusions 12 • Excellent safety profile met pre-specified target • Statistical superiority achieved in favor of treated group based on percent EWL • Statistically significant responder analyses based on pre- specified (20% and 25%) and “super-response” (50%) thresholds • ITT and per protocol analy

  13. Slide 13: Thank you

    Thank you

EnteroMedics — Technical Presentation (February 2013) on 6ix